Quotient Ltd. (NASDAQ:QTNT) shares hit a new 52-week low during trading on Friday . The stock traded as low as $5.67 and last traded at $6.06, with a volume of 643,835 shares traded. The stock had previously closed at $7.50.

Several research analysts have commented on QTNT shares. Zacks Investment Research lowered shares of Quotient from a “strong-buy” rating to a “hold” rating in a report on Wednesday, April 13th. Jefferies Group restated a “buy” rating and issued a $28.00 price objective on shares of Quotient in a report on Wednesday, June 1st.

The company has a 50-day moving average of $8.08 and a 200 day moving average of $9.30. The company’s market capitalization is $83.38 million.

Quotient (NASDAQ:QTNT) last announced its quarterly earnings results on Monday, May 23rd. The company reported ($0.41) earnings per share for the quarter, topping the consensus estimate of ($0.59) by $0.18. The business earned $5.05 million during the quarter. Equities research analysts predict that Quotient Ltd. will post ($2.20) earnings per share for the current fiscal year.

In related news, CFO Stephen Unger sold 14,484 shares of the business’s stock in a transaction on Friday, June 3rd. The shares were sold at an average price of $9.99, for a total value of $144,695.16. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, President Jeremy Stackawitz sold 15,000 shares of the business’s stock in a transaction on Thursday, June 9th. The stock was sold at an average price of $10.00, for a total transaction of $150,000.00. Following the completion of the sale, the president now owns 127,741 shares in the company, valued at approximately $1,277,410. The disclosure for this sale can be found here.

Quotient Limited is a commercial-stage diagnostics company. The Company is focused on blood grouping and serological disease screening. Blood grouping involves specific procedures performed at donor or patient testing laboratories to characterize blood, which includes antigen typing and antibody identification.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.